State Street’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $198M | Buy |
2,271,851
+73,236
| +3% | +$7.12M | 0.01% | 943 |
|
|
2025
Q4 | $235M | Buy |
2,198,615
+169,964
| +8% | +$18M | 0.01% | 851 |
|
|
2025
Q3 | $205M | Buy |
2,028,651
+121,050
| +6% | +$11.2M | 0.01% | 926 |
|
|
2025
Q2 | $121M | Sell |
1,907,601
-63,132
| -3% | -$3.87M | ﹤0.01% | 1202 |
|
|
2025
Q1 | $104M | Buy |
1,970,733
+129,863
| +7% | +$7.2M | ﹤0.01% | 1243 |
|
|
2024
Q4 | $103M | Sell |
1,840,870
-152,296
| -8% | -$8.41M | ﹤0.01% | 1312 |
|
|
2024
Q3 | $104M | Sell |
1,993,166
-10,716
| -0.5% | -$513K | ﹤0.01% | 1298 |
|
|
2024
Q2 | $82.3M | Sell |
2,003,882
-1,009,956
| -34% | -$40.3M | ﹤0.01% | 1385 |
|
|
2024
Q1 | $131M | Buy |
3,013,838
+807,820
| +37% | +$35.4M | 0.01% | 1143 |
|
|
2023
Q4 | $101M | Sell |
2,206,018
-159,838
| -7% | -$5.04M | ﹤0.01% | 1279 |
|
|
2023
Q3 | $54.2M | Sell |
2,365,856
-901,569
| -28% | -$20.2M | ﹤0.01% | 1573 |
|
|
2023
Q2 | $53.9M | Buy |
3,267,425
+655,237
| +25% | +$11.8M | ﹤0.01% | 1624 |
|
|
2023
Q1 | $46.6M | Sell |
2,612,188
-568,510
| -18% | -$14.3M | ﹤0.01% | 1700 |
|
|
2022
Q4 | $92.6M | Buy |
3,180,698
+52,793
| +2% | +$1.36M | 0.01% | 1203 |
|
|
2022
Q3 | $76.6M | Buy |
3,127,905
+2,876,846
| +1,146% | +$53.5M | ﹤0.01% | 1298 |
|
|
2022
Q2 | $1.04M | Sell |
251,059
-560,124
| -69% | -$3.07M | ﹤0.01% | 3623 |
|
|
2022
Q1 | $9.35M | Sell |
811,183
-1,119,907
| -58% | -$9.83M | ﹤0.01% | 2864 |
|
|
2021
Q4 | $19.3M | Sell |
1,931,090
-293,627
| -13% | -$3.3M | ﹤0.01% | 2499 |
|
|
2021
Q3 | $29.1M | Buy |
2,224,717
+45,630
| +2% | +$697K | ﹤0.01% | 2203 |
|
|
2021
Q2 | $42.7M | Sell |
2,179,087
-262,293
| -11% | -$5.45M | ﹤0.01% | 1962 |
|
|
2021
Q1 | $51.9M | Buy |
2,441,380
+1,162,261
| +91% | +$33.7M | ﹤0.01% | 1725 |
|
|
2020
Q4 | $38M | Buy |
1,279,119
+395,139
| +45% | +$10M | ﹤0.01% | 1816 |
|
|
2020
Q3 | $19.2M | Sell |
883,980
-252,512
| -22% | -$5.79M | ﹤0.01% | 2064 |
|
|
2020
Q2 | $25.3M | Buy |
1,136,492
+158,791
| +16% | +$3.1M | ﹤0.01% | 1905 |
|
|
2020
Q1 | $14.9M | Buy |
977,701
+45,181
| +5% | +$809K | ﹤0.01% | 2039 |
|
|
2019
Q4 | $21.4M | Buy |
932,520
+214,980
| +30% | +$4.78M | ﹤0.01% | 2092 |
|
|
2019
Q3 | $15.5M | Buy |
717,540
+113,164
| +19% | +$2.43M | ﹤0.01% | 2220 |
|
|
2019
Q2 | $13.3M | Buy |
604,376
+131,990
| +28% | +$3.33M | ﹤0.01% | 2345 |
|
|
2019
Q1 | $12.9M | Sell |
472,386
-12,637
| -3% | -$363K | ﹤0.01% | 2325 |
|
|
2018
Q4 | $13M | Sell |
485,023
-199,049
| -29% | -$5.5M | ﹤0.01% | 2274 |
|
|
2018
Q3 | $20M | Buy |
684,072
+481,187
| +237% | +$15.2M | ﹤0.01% | 2181 |
|
|
2018
Q2 | $6.34M | Buy |
202,885
+87,931
| +76% | +$2.4M | ﹤0.01% | 2751 |
|
|
2018
Q1 | $2.29M | Buy |
114,954
+17,660
| +18% | +$469K | ﹤0.01% | 3117 |
|
|
2017
Q4 | $2.83M | Buy |
+97,294
| New | +$2.57M | ﹤0.01% | 3053 |
|
Other funds holding RYTM
RCM
BBA
VPM
VCM
PA
State Street's RYTM Position: Q1 2026 in Review
State Street increased its Rhythm Pharmaceuticals (RYTM) stake by 3.3% in Q1 2026, buying an estimated $7.12M and bringing the position to 2,271,851 shares worth $198M. The position accounts for 0.01% of the portfolio, ranked #943.
State Street first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. The position peaked at $235M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.
- State Street held 2,271,851 shares of Rhythm Pharmaceuticals worth $198M as of Q1 2026.
- State Street bought 73,236 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $7.12M.
- Rhythm Pharmaceuticals made up 0.01% of State Street's portfolio in Q1 2026, its #943 holding.
- State Street first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- State Street's Rhythm Pharmaceuticals position peaked at $235M in Q4 2025.
- 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.